Compugen Ltd.
CGEN
Rank in Stocks
#16711
Compugen Ltd. is a clinical-stage biotechnology company engaged in the... Compugen Ltd. is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of innovative therapeutic candidates across Israel, the United States, and Europe. The company's primary focus is immuno-oncology, with a robust pipeline of investigational treatments. Key assets in their immuno-oncology portfolio include: COM701, an anti-PVRIG antibody, currently in Phase I clinical trials for the treatment of solid tumors. COM902, a therapeutic antibody targeting TIGIT, also in Phase I, being evaluated as a monotherapy in patients with advanced malignancies. Bapotulimab, an antibody designed to target ILDR2, which is undergoing Phase I clinical study for solid tumors. AZD2936, a novel bispecific antibody that targets both TIGIT and PD-1, advancing through Phase I/II clinical studies in patients with advanced or metastatic non-small cell lung cancer. Beyond these clinical-stage programs, Compugen is also pursuing early-stage immuno-oncology research, with a particular emphasis on myeloid targets. The company maintains significant strategic alliances, including: A collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against Compugen's proprietary immune checkpoint regulators. A partnership with Bristol-Myers Squibb to assess the safety and tolerability of COM701 when combined with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in advanced solid tumor patients. An engagement with Johns Hopkins School of Medicine to explore novel T cell and myeloid checkpoint targets. A licensing agreement with AstraZeneca for the development of bispecific and multispecific immuno-oncology antibody products. A research collaboration with Johns Hopkins University focusing on myeloid research. Compugen Ltd. was founded in 1993 and is headquartered in Holon, Israel.
Share Price
$2.14
Last synced: 2026-11-09
Market Cap
$197.09M
Change (1 day)
9.18%
Change (1 year)
24.42%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Compugen Ltd. (CGEN)
Category
Healthcare
Operating Margin for Compugen Ltd. (CGEN)
Operating Margin as of November 2026 TTM: 40.94%
According to Compugen Ltd.'s latest financial reports, its current operating margin (TTM) is 40.94%. At the end of 2025 the company had an operating margin of 43.05%.
Operating Margin history for Compugen Ltd. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 40.94% | -4.90% |
| 2025 | 43.05% | -180.56% |
| 2024 | -53.44% | 37.63% |
| 2023 | -38.83% | -91.77% |
| 2022 | -471.65% | -19.32% |
| 2021 | -584.57% | -62.88% |
| 2020 | -1,574.80% | 0.00% |
| 2019 | 0.00% | -100.00% |
| 2018 | -130.49% | 0.00% |
| 2017 | 0.00% | -100.00% |
| 2016 | -4,576.26% | 1,929.56% |
| 2015 | -225.48% | 126.02% |
| 2014 | -99.76% | -79.23% |
| 2013 | -480.22% | -91.42% |
| 2012 | -5,595.87% | -298.07% |
| 2011 | 2,825.24% | -499.86% |
| 2010 | -706.55% | -76.85% |
| 2009 | -3,051.60% | -20.12% |
| 2008 | -3,820.12% | -44.81% |
| 2007 | -6,922.22% | 6.36% |
| 2006 | -6,508.37% | 182.59% |
| 2005 | -2,303.10% | 495.41% |
| 2004 | -386.81% | 140.15% |
| 2003 | -161.07% | 18.81% |
| 2002 | -135.57% | -19.02% |
| 2001 | -167.42% | -28.68% |
| 2000 | -234.74% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.06% |
US
|
|
| -149.01% | -103.64% |
US
|
|
| 25.57% | -99.38% |
AU
|
|
| 31.23% | -99.24% |
BE
|
|
| 29.35% | -99.28% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Compugen Ltd.'s operating margin
What is Compugen Ltd.'s operating margin?
Compugen Ltd.'s operating margin is 40.94%, as of Nov 2026.
What was Compugen Ltd.'s operating margin in 2025?
In 2025, Compugen Ltd.'s operating margin was 43.05%, compared with -53.44% in 2024.
How has Compugen Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Compugen Ltd.'s operating margin was highest in 2025 (43.05%) and lowest in 2020 (-1,574.80%).
How does Compugen Ltd.'s operating margin compare with similar companies?
Compugen Ltd.'s operating margin (40.94%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.